Valuation : Unicycive Therapeutics, Inc.

Market Cap 153M 132M 123M 113M 212M 14.63B 213M 1.46B 570M 7.37B 575M 563M 24.41B P/E 2026 *
-4.55x
P/E 2027 * 3.41x
Enterprise Value 153M 132M 123M 113M 212M 14.63B 213M 1.46B 570M 7.37B 575M 563M 24.41B EV / Sales 2026 *
556x
EV / Sales 2027 * 1.05x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * 37.8%
1 day+1.29%
1 week+0.92%
Current month+9.78%
1 month+7.21%
3 months-22.21%
6 months-20.63%
Current year-4.68%
1 week 5.26
Extreme 5.26
5.64
1 month 4.71
Extreme 4.71
5.85
Current year 3.93
Extreme 3.93
8.74
1 year 3.71
Extreme 3.71
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
31.9
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 2016-08-17
Director of Finance/CFO 64 2021-02-28
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Chairman 53 2016-08-17
Director/Board Member 58 2017-12-31
Director/Board Member 58 2023-09-05
Date Insider Type Main position Quantity % Market Cap.
5/14/26 Free

Chief Executive Officer

762,200 3.0201%
8/25/25
Vivo Capital LLC
ConversionCompany 652,900 5.1135%
7/28/25 Free

Chief Executive Officer

325,000 2.5454%
Change 5-day change 1-year change 3-year change Capi.($)
+1.29%+0.92%+28.81%-28.53% 153M
+3.31%-3.70%+61.03%+103.64% 70.64B
-0.04%+0.55%+50.51%+93.14% 66.11B
-1.03%+0.46%+8.14%-5.28% 27.98B
-2.41%-2.95%-9.77%+455.82% 26.51B
+0.30%-0.69%+63.18%+11.93% 26.44B
+1.02%+6.43%+269.42%+420.34% 20.4B
+0.65%+1.44%+35.32%-17.03% 20.17B
-1.91%-4.37%+13.33%+531.29% 15.99B
-1.50%+2.92%+43.50%+151.30% 13.69B
Average -0.03%+0.98%+56.35%+171.66% 28.81B
Weighted average by Cap. +0.45%+0.65%+56.62%+154.56%

Financials

2026 *2027 *
Net sales 275K 236K 221K 203K 382K 26.3M 383K 2.62M 1.02M 13.26M 1.03M 1.01M 43.87M 145M 125M 117M 107M 202M 13.89B 202M 1.38B 541M 7B 546M 534M 23.16B
Net income -34.12M -29.29M -27.42M -25.11M -47.3M -3.26B -47.43M -325M -127M -1.64B -128M -125M -5.44B 46.27M 39.71M 37.18M 34.05M 64.14M 4.42B 64.32M 440M 172M 2.23B 174M 170M 7.37B
Net Debt - -
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
26-08-27 $5.500 +1.29% 366,162
26-08-26 $5.430 -0.73% 906,196
26-08-25 $5.470 +2.43% 417,050
26-08-24 $5.340 -5.15% 742,955
26-08-21 $5.630 +3.30% 1,013,180
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.500USD
Average target price
28.22USD
Spread / Average Target
+413.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock